SCM
SYRE icon

Soleus Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Soleus Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Buy
+147,000
New +$10.7M 0.45% 52
2020
Q3 		– Sell
-14,794
Closed -$3.42M – 74
2020
Q2 		$3.42M Sell
14,794
-6,666
-31% -$1.27M 1.95% 16
2020
Q1 		$2.5M Buy
21,460
+3,133
+17% +$533K 2.91% 13
2019
Q4 		$3.5M Buy
+18,327
New +$3.6M 3.38% 8

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Soleus Capital Management's SYRE Position: Q2 2026 in Review

Soleus Capital Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 147,000 shares worth $13.1M. The stake represents 0.45% of the portfolio and ranks #52 among its holdings. This is a return to the name: Soleus Capital Management previously reported a position in SYRE as recently as Q2 2020.

Soleus Capital Management first reported a position in SYRE in Q4 2019 and has held it in 4 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Soleus Capital Management held 147,000 shares of Spyre Therapeutics worth $13.1M as of Q2 2026.
  • Spyre Therapeutics was a new Soleus Capital Management position in Q2 2026.
  • Spyre Therapeutics made up 0.45% of Soleus Capital Management's portfolio in Q2 2026, its #52 holding.
  • Soleus Capital Management first reported a position in Spyre Therapeutics in Q4 2019 and has held it in 4 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.